Retour
Redhill Biopharma Ltd (RDHL) Gagner
Graphique du cours de l'action RDHL
RDHL Gagner
Redhill Biopharma Ltd
$0.88
1.71%
$0.01
À la fermeture : Mar 24, 16:00:00 GMT-4
$0.88
0%
$0
Post-Marché: Mar 24, 20:00:00 GMT-4
Statistiques clés
Clôture préc.
$0.8749
Prix d'ouverture
$0.8899
Plage de la journée
$0.87 - $0.8899
Plage de 52 semaines
$0.8 - $3.31
Volume
7.2K
Volume moyen
493.7K
Rendement en dividend
--
BPA (TTM)
-0.00
Capitalisation boursière
$4.5M
Qu’est-ce que RDHL ?
RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Fonctionnalités
Ressources
© 2026 Finture Development Limited. Tous droits réservés.